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The International Society for Pharmacoeconomics
and Outcomes Research (ISPOR) Randomized
Clinical Trials-Cost-Effectiveness Analysis (RCT-
CEA) task force report contains a comprehensive
discussion of the methodological issues arising in
conducting economic evaluations alongside clinical
trials. The report is intended to be relevant to all
trials, from exploratory (efﬁcacy) studies to prag-
matic (effectiveness) studies, although the authors
acknowledge that the former studies are in the
majority.
Given the comprehensive coverage of issues, the
discussion of many of them is, of necessity, brief.
However, in most cases, especially in respect of the
statistical issues, the discussion is very clear. Also,
the authors give an extensive list of references for
those wanting a more detailed discussion of partic-
ular points. Probably the most important original
contribution is the set of reporting guidelines given
towards the end of the paper. This forms a useful
checklist which I would recommend the authors of
trial-based economic evaluations to consult before
submitting their paper to a journal.
I found little that I disagreed with in the report. If
I did have a frustration it was that, on several occa-
sions, issues were discussed but no deﬁnite view
given on the best way forward. For example, should
we collect data on patients’ preferences in clinical
trials, or should we rely on the generic utility instru-
ments, the majority of which employ a tariff based
on preferences from the general public? Of course,
this lack of ﬁrm recommendations probably reﬂects
the consensus nature of the document, in contrast
with the more prescriptive guidelines for economic
evaluation issued by bodies such as the National
Institute for Health and Clinical Excellence (NICE)
in the United Kingdom [1].
More broadly, the task force report brieﬂy
touches on two issues that merit further discussion.
First, where do trial-based economic evaluations sit
vis-à-vis other approaches to economic evaluation,
in particular decision-analytic modeling? The
authors acknowledge that “clinical trials are artiﬁ-
cial treatment environments, and do not provide all
the economic information needed by decision mak-
ers.” However, in their conclusions they state that
“conducting high quality economic analyses along-
side clinical studies is desirable because they provide
timely information with high internal validity.”
Striking the right balance between trial-based
and modeling studies is important to the continuing
success of economic evaluation. In the past, decision
makers have been highly suspicious of modeling
studies, but I sense that this view is slowly changing,
perhaps because of the development of explicit
standards for such studies [2]. Where does this leave
trial-based evaluations? My sense is that, in the
future, they are more likely to be regarded as excel-
lent opportunities to gather high quality patient-
level data, rather than studies that provide all the
data required for a particular decision.
Secondly, the Task Force points out that, while
“economic analysis is rarely the primary purpose of
an experimental study, it is important that the ana-
lyst contributes to the design of the study to ensure
that the structure of the trial will provide the data
necessary for a high quality economic study.” I
wonder if the time has come for economists to be
much more assertive about the changes in trial
design they would like to see. My reasoning is that,
although drug licensing remains the motivation for
most clinical trials, reimbursement decisions are
gaining more prominence.
Because the reimbursement decisions are made
soon after approval to market has been granted in
many settings, it makes sense to anticipate these
decisions in trial design. The means: 1) ensuring
that the trial compares the technology of interest
with the relevant alternative clinical strategies; 2)
measuring end points that have relevance to the
patient and/or payer; and 3) conducting the trial
over a period of time long enough to assess changes
in the relevant end points.
It was noticeable that, in the recent reappraisal of
the drugs for Alzheimer’s disease (AD), NICE
remarked that “the clinical evidence base for
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acetylcholinesterase inhibitors has matured and that
it demonstrates a consistent gain on cognitive and
global scales compared with placebo in mild to
moderate AD.” Nevertheless, it also noted that
“these gains were small on many of the measures of
effect,” that “there is little positive randomized
evidence available on the long-term gain,” and that
“the RCT evidence on outcomes of importance to
patients and caregivers, such as quality of life and
time to institutionalization, was limited and largely
inconclusive” [3].
In summary, the report of the ISPOR RCT-CEA
Task Force clearly demonstrates that economists
have thought about, and begun to grapple with, the
methodologic issues of undertaking economic anal-
ysis alongside clinical trials. In my view the next
step is to take the trials themselves to task, by argu-
ing for design changes that will generate more
relevant data for patients, clinicians, and health-
care payers.
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